Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BI 695502
Drug: Avastin

First Posted Date: 2014-10-23

Last Posted Date: 2020-01-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 671

Registration Number: NCT02272413

Locations: 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
Southern California Oncology Research Alliance, Los Angeles, California, United States
🇺🇦
CI Zapor Reg Cl Oncological Dispensary of ZRC, Zhaporizhzhia, Zhaporizhzhia, Ukraine

and more 186 locations

Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam, tablet
Drug: Crobenetine, i.v. infusion
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02269202

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIII 890 CL
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 73

Registration Number: NCT02269215

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Low dose of losartan
Drug: Low dose of telmisartan
Drug: High dose of telmisartan
Drug: High dose of losartan

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 330

Registration Number: NCT02269176

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: BIIL 284 BS, low dose
Drug: BIIL 284 BS, high dose
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02269189

Tolerability of Asasantin in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin ER
Drug: Placebo

First Posted Date: 2014-10-21

Last Posted Date: 2014-10-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT02269228

Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Asasantin®
Drug: Acetylsalicylic acid high dose
Drug: Acetylsalicylic acid low dose

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT02268773

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIIL 284 BS
Drug: Placebo
Drug: Prednisone

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT02268149

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BIIB 722 CL

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10

Registration Number: NCT02268604

Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILN 2061 ZW single rising doses
Drug: BILN 2061 ZW fixed dose
Drug: Placebo
Other: Standardized breakfast

First Posted Date: 2014-10-20

Last Posted Date: 2014-10-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 103

Registration Number: NCT02268760

AI-Powered Research

Premium Access

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Tolerability of Asasantin in Healthy Female and Male Subjects

Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers

Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect